Results 71 to 80 of about 5,133,442 (399)

Hendrickson Class II Palatal Fracture Following a Road Trauma Accident in a Pediatric Patient

open access: yesCase Reports in Pediatrics
Pediatric palatal fractures are rare clinical presentations owing to the relative plasticity of their bones. We present a case of a 3-year-old pedestrian struck male patient presenting with a mid-sagittal palatal fracture which corresponds to a ...
Zilefac Brian Ngokwe   +4 more
doaj   +1 more source

Effects of Low-Level Laser Therapy on Osseous Defects Distal to Mandibular Second Molar after Extraction of Impacted Third Molar

open access: yesApplied Bionics and Biomechanics, 2022
Objective. To evaluate the efficiency of low-level laser therapy on the distal osseous defects of the mandibular second molar (M2) after the adjacent impacted third molar (M3) extraction. Methods.
Ling-Yu Li   +4 more
doaj   +1 more source

Stem cells and oral surgery: A systematic review

open access: yesJournal of Clinical and Experimental Dentistry, 2019
Background Considering the structural loss that occurs after surgical procedures for cystic and tumoral pathology, in periodontitis, as well as the maxillary atrophy that determines the rehabilitation with dental implants, it is imperative to find ...
Regina Mosquera-Pérez   +5 more
semanticscholar   +1 more source

Prosthetic management of mid-facial defect with magnet-retained silicone prosthesis [PDF]

open access: yes, 2013
Background and aim: Mid-facial defect is one of the most disfiguring and impairing defects. A design of prosthesis that is aesthetic and stable can be precious to a patient who has lost part of his face due to surgical excision.
Buzayan, M. M.
core   +2 more sources

Molecular imaging predicts trastuzumab‐deruxtecan (T‐DXd) response in head and neck cancer xenograft models

open access: yesMolecular Oncology, EarlyView.
Trastuzumab‐deruxtecan, a HER2‐targeting antibody‐drug conjugate, shows promising antitumor activity in head and neck squamous cell carcinoma with low HER2 expression. In vitro and in vivo studies demonstrated dose‐dependent cell death and tumor growth reduction in low HER2‐expressing cell lines, which correlated with drug accumulation measured using a
Abdullah Bin Naveed   +8 more
wiley   +1 more source

Pingyangmycin Activates Oral Carcinoma Cell Autophagy via the Phosphorylation of the PI3K/AKT/mTOR Axis to Achieve the Purpose of Treating Oral Carcinoma

open access: yesEmergency Medicine International, 2022
Objective. The aim of the study is to investigate the role of pingyangmycin (PYM) in oral carcinoma (OC) cell autophagy via the PI3K/AKT/mTOR axis. Methods. 200 μL PYM culture solution with a concentration of 100 μg/ml (low PYM (L-PYM) group), 300 μg/ml (
Wei Xu   +4 more
doaj   +1 more source

Unraveling LINE‐1 retrotransposition in head and neck squamous cell carcinoma

open access: yesMolecular Oncology, EarlyView.
The novel RetroTest method allows the detection of L1 activation in clinical samples with low DNA input, providing global L1 activity and the identification of the L1 source element. We applied RetroTest to a real‐world cohort of HNSCC patients where we reported an early L1 activation, with more than 60% of T1 patients showing L1 activity.
Jenifer Brea‐Iglesias   +12 more
wiley   +1 more source

Intramuscular Myxoma of the Intrinsic Muscles of the Tongue: A Case Report with Literature Review

open access: yesCase Reports in Dentistry, 2022
Myxoma is a benign tumor of mesenchymal origin. It frequently occurs in the muscles of the hip and extremities; however, it rarely occurs in the head and neck region. This report describes the second case of an intramuscular myxoma of the tongue.
Naoko Tsunoda   +6 more
doaj   +1 more source

Simultaneous inhibition of TRIM24 and TRIM28 sensitises prostate cancer cells to antiandrogen therapy, decreasing VEGF signalling and angiogenesis

open access: yesMolecular Oncology, EarlyView.
TRIM24 and TRIM28 are androgen receptor (AR) coregulators which exhibit increased expression with cancer progression. Both TRIM24 and TRIM28 combine to influence the response of castrate‐resistant prostate cancer (CRPC) cells to AR inhibitors by mediating AR signalling, regulation of MYC and upregulating VEGF to promote angiogenesis. Castrate‐resistant
Damien A. Leach   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy